Ipsen released Q1 FY17 trading results which were ahead of our estimates as well as the market consensus. Revenue at CER increased by 19.1% (vs AV’s estimate: +17.7%), on the back of a robust performance in the speciality care segment (+25.4% vs AV’s estimate: +22.4%; accounts for c.84% of Q1 17 sales). Within the segment, the primary growth contributor was Somatuline (+36.6% vs AV’s estimate: +25%; accounts for c.39% of Q1 17 sales), led by strong volume growth in Europe an
09 May 2017
Strong operating performance lays the foundation for long-term growth
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong operating performance lays the foundation for long-term growth
Ipsen SA (IPN:WBO) | 0 0 5.0% | Mkt Cap: 10,144m
- Published:
09 May 2017 -
Author:
Nishant Choudhary -
Pages:
4
Ipsen released Q1 FY17 trading results which were ahead of our estimates as well as the market consensus. Revenue at CER increased by 19.1% (vs AV’s estimate: +17.7%), on the back of a robust performance in the speciality care segment (+25.4% vs AV’s estimate: +22.4%; accounts for c.84% of Q1 17 sales). Within the segment, the primary growth contributor was Somatuline (+36.6% vs AV’s estimate: +25%; accounts for c.39% of Q1 17 sales), led by strong volume growth in Europe an